Lincoln-based NHO Revive is proud to announce its selection as the only clinical research site in Nebraska participating in INTerpath-011 a global, Phase 2 Open-label Randomized Study of V940 in Combination with BCG Versus BCG Monotherapy in Participants with High-risk Non-Muscle Invasive Bladder Cancer.
The study is sponsored by Merck Sharp & Dohme LLC (Merck). V940 (mRNA-4157) was developed using mRNA technology initially pioneered by Moderna. As the sole Nebraska site, NHO Revive continues to break ground by bringing next-generation treatment options directly to the region’s patients, treatments that are often only available at large academic institutions or out-of-state centers.
The trial tests an investigational combination including mRNA-based cancer vaccine designed to stimulate the immune system to recognize and attack tumor-specific neoantigens. Adjuvant therapies given after primary cancer treatment are critical in preventing recurrence, especially in high-risk populations. Unlike traditional adjuvant treatments, this novel approach harnesses mRNA to deliver personalized instructions to the immune system.
“This trial represents a major step forward in how we could think about treating high-risk non-muscle invasive bladder cancer (NMIBC),” said Dr. Kailash Mosalpuria, Medical Oncologist at Nebraska Hematology-Oncology. “By combining standard BCG with a personalized mRNA vaccine to target cancer more precisely, we’re offering patients here in Nebraska the opportunity to test tomorrow’s treatments today.”
NHO Revive is committed to contributing to the development of life-extending therapies and to ensuring that patients have access to promising investigational treatments close to home.
About V940 (mRNA-4157)
V940 (mRNA-4157) is an investigational, personalized mRNA neoantigen vaccine (an individualized neoantigen therapy) that consists of a single lipid-encapsulated mRNA encoding up to 34 patient-specific neoantigens. The vaccine is designed to be translated by the patient’s cells and presented by antigen-presenting cells to stimulate neoantigen-specific T-cell responses; in INTerpath-011 it is being evaluated to enhance the antitumor activity of intravesical BCG in high-risk non-muscle invasive bladder cancer.
About High-risk Non-Muscle Invasive Bladder Cancer (NMIBC)
High-risk NMIBC is an early form of bladder cancer in which abnormal cells are confined to the inner lining of the bladder but carry a significant chance of recurrence and progression to muscle-invasive disease. Patients are considered “high-risk” if they have features such as carcinoma in situ (CIS), high-grade tumors, or multiple and/or large lesions. Standard care includes surgery and BCG therapy, yet many patients still face relapse, making new treatment options urgently needed.
About NHORevive
NHO Revive is a joint initiative between Nebraska Hematology Oncology (NHO) and Revive Research Institute, combining decades of clinical expertise and pioneering research.
About Nebraska Hematology Oncology
Nebraska Hematology-Oncology has been serving Lincoln and surrounding communities since 1997. With five Physicians, 15 Advanced Practice Providers and over 140 staff committed to person-first care, NHO has gained a reputation for being a leading care facility for cancer and blood disorders in the Midwest. As the first QOPI-certified and ASCO Patient-Centered Cancer Care-certified clinic in Nebraska, NHO has been identified as a cancer center that meets the highest standards for quality cancer care. More information about NHO can be found at YourCancerCare.com.
# # #
